Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TERN-701 |
Synonyms | |
Therapy Description |
TERN-701 is a selective BCR-ABL1 inhibitor with activity against the T315I mutation, which potentially inhibits tumor cell proliferation (Blood (2023) 142 (Supplement 1): 5757). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TERN-701 | HS-10382|HS 10382|HS10382|TERN701|TERN 701 | BCR-ABL Inhibitor 32 | TERN-701 is a selective BCR-ABL1 inhibitor with activity against the T315I mutation, which potentially inhibits tumor cell proliferation (Blood (2023) 142 (Supplement 1): 5757). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06163430 | Phase I | TERN-701 | CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia | Not yet recruiting | USA | 0 |